United Kingdom

Kaken Pharmaceutical Co Ltd (4521.T)

4521.T on Tokyo Stock Exchange

23 Aug 2019
Change (% chg)

¥5 (+0.10%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Kaken Pharmaceutical says distribution agreement for Clenafin in Hong Kong and Macau
Tuesday, 2 Oct 2018 

Oct 2(Reuters) - Kaken Pharmaceutical Co Ltd <4521.T>:Says Kaken Pharmaceutical Co Ltd (Kaken) and Main Life Corp., Ltd. (Main Life) announced today that Kaken and Main Life concluded an exclusive distribution agreement for the topical formulation for Onychomycosis “Clenafin/Jublia” in Hong Kong and Macau.  Full Article

Kaken Pharmaceutical signs exclusive distribution agreement for Clenafin/Jublia in Taiwan
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Kaken Pharmaceutical Co Ltd <4521.T>:Says co signed an exclusive distribution agreement with Tai Tien Pharmaceuticals Co Ltd (Tai Tien), which is a subsidiary of Mitsubishi Tanabe Pharma Corporation <<<4508.T>>>, for the topical formulation for Onychomycosis "Clenafin/Jublia" (product) in Taiwan.According to the agreement, co grants to Tai Tien the exclusive right for sales of the product in Taiwan and Tai Tien expects to launch the product in 2018.  Full Article